Satraplatin 60215 Erlotinib HCl potently inhibits EGFR

Erlotinib HCl potently inhibits EGFR activation in intact cells including HNS human head and neck tumor cells (IC50 20nM)

At low concentrations

This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis

11a-dimethyl-7-oxo-hexadecahydro-1H-cyclopenta[a]phenanthren-1-yl 2-[2-(2-{2-[(2S)-2-[(2S

2017 May 15

Satraplatin 60215 Erlotinib HCl potently inhibits EGFRSatraplatin, also known as JM216 and BMS182751, is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. It has not yet received approval from the U. S. Food and Drug Administration. First mentioned in the medical literature in 1993, satraplatin is the first orally active platinum based chemotherapeutic drug; other available platinum